Basilea Pharmaceutic (BPMUF) 70.4100 $BPMUF
Basilea reports presentation of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
GlobeNewswire - Fri Apr 15, 12:25AM CDT
-- Post-hoc analysis on clinical response of ceftobiprole in staphylococcal bacteremia
Global Melanoma Pipeline Review 2015
M2 - Tue Feb 09, 10:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/xdhrqg/melanoma) has announced the addition of the "Melanoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Melanomaand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - MelanomaOverview - Therapeutics Development - Pipeline Products for Melanoma - Overview - Pipeline Products for Melanoma - Comparative Analysis - Melanoma - Therapeutics under Development by Companies - Melanoma - Therapeutics under Investigation by Universities/Institutes - Melanoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Melanoma - Products under Development by Companies - Melanoma - Products under Investigation by Universities/Institutes - Melanoma - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - AB Science SA - AbbVie Inc. - ACF Pharmaceuticals, LLC - Adamis Pharmaceuticals Corporation - Adaptimmune Limited - Aduro BioTech, Inc. - Advaxis, Inc. - Aeterna Zentaris Inc. - Affichem SA - Agalimmune Ltd - Agenus, Inc. - Agilvax, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - Altor BioScience Corporation - Amgen Inc. - Anavex Life Sciences Corp. - Antigen Express, Inc. - APEIRON Biologics AG - Aphios Corporation - APO-T B.V. - Aposense Ltd. - Applied Immune Technologies Ltd - Aptose Biosciences Inc. - Arisaph Pharmaceuticals, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Axelar AB - Azaya Therapeutics, Inc. - Basilea Pharmaceutica AG For more information visit http://www.researchandmarkets.com/research/xdhrqg/melanoma
ADXS: 8.51 (+0.48), ADRO: 11.48 (+0.21), ARWR: 5.88 (+0.14), ADMP: 2.87 (-0.16), AMGN: 150.65 (+1.03), APTO: 2.69 (-0.01), AVXL: 4.11 (+0.09), AZN: 28.42 (+0.84), ABBV: 60.11 (+0.10), ARRY: 3.28 (+0.03)
Psoriasis Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 8:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/6tv9lw/psoriasis) has announced the addition of the "Psoriasis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriasisand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - PsoriasisOverview - Therapeutics Development - Pipeline Products for Psoriasis- Overview - Pipeline Products for Psoriasis- Comparative Analysis - Psoriasis- Therapeutics under Development by Companies - Psoriasis- Therapeutics under Investigation by Universities/Institutes - Psoriasis- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Psoriasis- Products under Development by Companies - Psoriasis- Products under Investigation by Universities/Institutes - Psoriasis- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 3SBio Inc. - 4SC AG - Abeome Corporation - AbGenomics International, Inc. - ADC Therapeutics Sarl - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Ajinomoto Pharmaceuticals Co., Ltd. - AlbireoPharma - Allozyne, Inc. - Almirall, S.A. - Amgen Inc. - Anacor Pharmaceuticals, Inc. - AnaptysBio, Inc. - Arena Pharmaceuticals, Inc. - Argos Therapeutics, Inc. - Arrien Pharmaceuticals, LLC - AstraZeneca Plc - Athenex, Inc. - Aurigene Discovery Technologies Limited - Avesthagen Limited - Avexxin AS - Basilea Pharmaceutica AG - BIOCAD - Biocon Limited - BioLingus AG - BioMAS Ltd. - Bionomics Limited - Bionovis SA - Boehringer Ingelheim GmbH - Brickell Biotech, Inc. - Bristol-Myers Squibb Company - Can-Fite BioPharma Ltd. - Celgene Corporation - Cellceutix Corporation For more information visit http://www.researchandmarkets.com/research/6tv9lw/psoriasis
AMGN: 150.65 (+1.03), BMY: 70.96 (+0.29), CANF: 2.67 (+0.05), ARGS: 5.71 (+0.10), AZN: 28.42 (+0.84), ANAC: 99.26 (+0.09), ARNA: 1.90 (+0.06), CELGZ: 1.45 (-0.02)
Colorectal Cancer Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/44bmjz/colorectal_cancer) has announced the addition of the "Colorectal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colorectal Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Colorectal CancerOverview - Therapeutics Development - Pipeline Products for Colorectal Cancer- Overview - Pipeline Products for Colorectal Cancer- Comparative Analysis - Colorectal Cancer- Therapeutics under Development by Companies - Colorectal Cancer- Therapeutics under Investigation by Universities/Institutes - Colorectal Cancer- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Colorectal Cancer- Products under Development by Companies - Colorectal Cancer- Products under Investigation by Universities/Institutes - Colorectal Cancer- Companies Involved in Therapeutics Development Companies Mentioned - Sample List of the 200 Companies Featured - 2cureX ApS - 3-V Biosciences, Inc. - 4SC AG - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Actinium Pharmaceuticals, Inc. - Adamed Sp. z o.o. - Advaxis, Inc. - Advenchen Laboratories, LLC - Alchemia Limited - Allinky Biopharma - Amgen Inc. - Antibe Therapeutics, Inc. - Apexigen, Inc. - Aphios Corporation - Aposense Ltd. - Arisaph Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Bavarian Nordic A/S - Baxalta Incorporated - Bayer AG - BeiGene(Beijing) Co.,Ltd - BioAtla, LLC - Biocon Limited - Bionomics Limited - Bionovis SA - Biotecnol, Inc. For more information visit http://www.researchandmarkets.com/research/44...tal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ADXS: 8.51 (+0.48), ARQL: 1.75 (-0.04), AMGN: 150.65 (+1.03), ATNM: 1.77 (-0.03), AZN: 28.42 (+0.84), AVEO: 1.01 (-0.01), ABBV: 60.11 (+0.10), BXLT: 46.02 (-0.18), ARRY: 3.28 (+0.03)
Inflammatory Bowel Disease Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/bgntqd/inflammatory) has announced the addition of the "Inflammatory Bowel Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Inflammatory Bowel Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Inflammatory Bowel Disease Overview - Therapeutics Development - Pipeline Products for Inflammatory Bowel Disease - Overview - Pipeline Products for Inflammatory Bowel Disease - Comparative Analysis - Inflammatory Bowel Disease - Therapeutics under Development by Companies - Inflammatory Bowel Disease - Therapeutics under Investigation by Universities/Institutes - Inflammatory Bowel Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Inflammatory Bowel Disease - Products under Development by Companies - Inflammatory Bowel Disease - Products under Investigation by Universities/Institutes - Inflammatory Bowel Disease - Companies Involved in Therapeutics Development Sample List of the 180 Companies - 4D Pharma Plc - 4SC AG - AB Science SA - AbbVie Inc. - Advinus Therapeutics Ltd. - Aerpio Therapeutics, Inc. - Ajinomoto Pharmaceuticals Co., Ltd. - Akari Therapeutics, Plc - Alba Therapeutics Corporation - AlbireoPharma - Alfa Wassermann S.p.A - Allozyne, Inc. - Altheus Therapeutics, Inc. - Alvine Pharmaceuticals, Inc. - Am-Pharma B.V. - Amakem NV - Amgen Inc. - Amorepacific Corporation - Ampio Pharmaceuticals, Inc. - Amyra Biotech AG - Apogee Biotechnology Corporation - Ardelyx, Inc. - Arena Pharmaceuticals, Inc. - Argos Therapeutics, Inc. - AskAt Inc. - Astellas Pharma Inc. - Atlantic Healthcare Plc - Avaxia Biologics, Inc. - Axxam SpA - Basilea Pharmaceutica AG - BioAtla, LLC - BIOCAD - BioLineRx, Ltd. - BioLingus AG - Bionovis SA - Biotec Pharmacon ASA - BioTherapeutics Inc. For more information visit http://www.researchandmarkets.com/research/bg...flammatory
ARGS: 5.71 (+0.10), AMGN: 150.65 (+1.03), AMPE: 3.22 (unch), ABBV: 60.11 (+0.10), AKTX: 14.61 (unch), ARNA: 1.90 (+0.06)
Basilea announces that European Commission approves isavuconazole (CRESEMBA(r)) as a treatment for invasive aspergillosis and mucormycosis in the European Union
GlobeNewswire - Fri Oct 16, 9:55AM CDT
-- Basilea's second anti-infective product approved in Europe, providing potential commercial synergy with Zevtera(R) (ceftobiprole)
Basilea signs exclusive distribution agreement for Zevtera(R) (ceftobiprole medocaril) in the Middle East and North Africa with Hikma Pharmaceuticals LLC
Thomson Reuters ONE - Thu Oct 15, 12:15AM CDT
Basilea Pharmaceutica AG / Basilea signs exclusive distribution agreement for Zevtera(R) (ceftobiprole medocaril) in the Middle East and North Africa with Hikma Pharmaceuticals LLC . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Basilea announces that Health Canada approved ZEVTERA(r) for the treatment of bacterial lung infections
GlobeNewswire - Mon Oct 12, 12:18AM CDT
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Health Canada has approved ZEVTERA (ceftobiprole medocaril) for the treatment of patients 18 years of age and older with hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP), and for the treatment of community-acquired pneumonia (CAP).
Gastric Cancer - Pipeline Review, H2 2015 Featuring Over 100 Companies
M2 - Mon Oct 05, 5:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lhb64g/gastric_cancer) has announced the addition of the "Gastric Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastric Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - 30 of the 100 Companies - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - AlphaVax, Inc. - Ambrx, Inc. - Amgen Inc. - Aslan Pharmaceuticals Pte. Ltd. - Astellas Pharma Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Azaya Therapeutics Incorporated - Basilea Pharmaceutica AG - Bayer AG - BioMarin Pharmaceutical Inc. - Biotecnol, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - cCAM Biotherapeutics Ltd. - Celgene Corporation - Celldex Therapeutics, Inc. - Cellectar Biosciences, Inc. - Celltrion, Inc. - Celon Pharma Sp. z o.o. - Cerulean Pharma, Inc. - Chipscreen Biosciences Ltd - Chugai Pharmaceutical Co., Ltd. - Curaxys, S.L. For more information visit http://www.researchandmarkets.com/research/lh...ric_cancer
CLRB: 3.54 (-0.10), ADXS: 8.51 (+0.48), BMRN: 84.06 (+0.20), CERU: 2.12 (+0.02), AMBX: (), CLDX: 4.41 (+0.14), AMGN: 150.65 (+1.03), BMY: 70.96 (+0.29), AZN: 28.42 (+0.84), AVEO: 1.01 (-0.01), ABBV: 60.11 (+0.10), CELGZ: 1.45 (-0.02)
Basilea announces development of inhaled dosage form of its Gram-negative antibiotic BAL30072 as part of European iABC program
GlobeNewswire - Mon Sep 07, 12:20AM CDT
-- Start of "inhaled Antibiotics in Bronchiectasis and Cystic fibrosis" (iABC) program to develop new antibiotic treatments for cystic fibrosis and bronchiectasis
Colorectal Cancer - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Colorectal Cancer
M2 - Fri Aug 14, 5:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dvsdxp/colorectal_cancer) has announced the addition of the "Colorectal Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colorectal Cancer and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - A review of the Colorectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Key Topics Covered: - Colorectal Cancer Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - 2cureX ApS - 3-V Biosciences, Inc. - 4SC AG - AB Science - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Adamed Sp. z o.o. - Advaxis, Inc. - Advenchen Laboratories, LLC - Aeterna Zentaris Inc. - Alchemia Limited - Allinky Biopharma - Amgen Inc. - Angiogene Pharmaceuticals Limited - Antibe Therapeutics, Inc. - Aphios Corporation - Arisaph Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Bavarian Nordic A/S - Bayer AG - Beta Cat Pharmaceuticals, LLC - Biocon Limited - Bionomics Limited - BioNovion B.V. - Biothera, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company For more information visit http://www.researchandmarkets.com/research/dv...tal_cancer
ADXS: 8.51 (+0.48), ARQL: 1.75 (-0.04), AMGN: 150.65 (+1.03), BMY: 70.96 (+0.29), ATNM: 1.77 (-0.03), AZN: 28.42 (+0.84), AVEO: 1.01 (-0.01), ABBV: 60.11 (+0.10), ARRY: 3.28 (+0.03)
Basilea reports 2015 half-year results - Major milestones achieved for CRESEMBA(R) and Zevtera(R)
Thomson Reuters ONE - Fri Aug 14, 12:15AM CDT
Basilea Pharmaceutica AG / Basilea reports 2015 half-year results - Major milestones achieved for CRESEMBA(R) and Zevtera(R) . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of lung and skin infections
GlobeNewswire - Wed Aug 12, 12:20AM CDT
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) designated its investigational drug ceftobiprole as a Qualified Infectious Disease Product. The designation relates to the potential use of the drug in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Basilea reports topline results of isavuconazole phase 3 study in candidemia and other invasive Candida infections
Thomson Reuters ONE - Thu Jul 30, 12:15AM CDT
Basilea Pharmaceutica AG / Basilea reports topline results of isavuconazole phase 3 study in candidemia and other invasive Candida infections . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Basilea announces that CHMP recommends approval of isavuconazole (CRESEMBA(R)) as a treatment for invasive aspergillosis and mucormycosis in the European Union
Thomson Reuters ONE - Fri Jul 24, 6:46AM CDT
Basilea Pharmaceutica AG / Basilea announces that CHMP recommends approval of isavuconazole (CRESEMBA(R)) as a treatment for invasive aspergillosis and mucormycosis in the European Union . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Basilea reports presentation of isavuconazole and ceftobiprole data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
GlobeNewswire - Fri Apr 15, 12:25AM CDT
-- Post-hoc analysis on clinical response of ceftobiprole in staphylococcal bacteremia
Global Melanoma Pipeline Review 2015
M2 - Tue Feb 09, 10:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/xdhrqg/melanoma) has announced the addition of the "Melanoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Melanomaand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - MelanomaOverview - Therapeutics Development - Pipeline Products for Melanoma - Overview - Pipeline Products for Melanoma - Comparative Analysis - Melanoma - Therapeutics under Development by Companies - Melanoma - Therapeutics under Investigation by Universities/Institutes - Melanoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Melanoma - Products under Development by Companies - Melanoma - Products under Investigation by Universities/Institutes - Melanoma - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - AB Science SA - AbbVie Inc. - ACF Pharmaceuticals, LLC - Adamis Pharmaceuticals Corporation - Adaptimmune Limited - Aduro BioTech, Inc. - Advaxis, Inc. - Aeterna Zentaris Inc. - Affichem SA - Agalimmune Ltd - Agenus, Inc. - Agilvax, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - Altor BioScience Corporation - Amgen Inc. - Anavex Life Sciences Corp. - Antigen Express, Inc. - APEIRON Biologics AG - Aphios Corporation - APO-T B.V. - Aposense Ltd. - Applied Immune Technologies Ltd - Aptose Biosciences Inc. - Arisaph Pharmaceuticals, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Axelar AB - Azaya Therapeutics, Inc. - Basilea Pharmaceutica AG For more information visit http://www.researchandmarkets.com/research/xdhrqg/melanoma
ADXS: 8.51 (+0.48), ADRO: 11.48 (+0.21), ARWR: 5.88 (+0.14), ADMP: 2.87 (-0.16), AMGN: 150.65 (+1.03), APTO: 2.69 (-0.01), AVXL: 4.11 (+0.09), AZN: 28.42 (+0.84), ABBV: 60.11 (+0.10), ARRY: 3.28 (+0.03)
Psoriasis Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 8:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/6tv9lw/psoriasis) has announced the addition of the "Psoriasis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriasisand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - PsoriasisOverview - Therapeutics Development - Pipeline Products for Psoriasis- Overview - Pipeline Products for Psoriasis- Comparative Analysis - Psoriasis- Therapeutics under Development by Companies - Psoriasis- Therapeutics under Investigation by Universities/Institutes - Psoriasis- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Psoriasis- Products under Development by Companies - Psoriasis- Products under Investigation by Universities/Institutes - Psoriasis- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 3SBio Inc. - 4SC AG - Abeome Corporation - AbGenomics International, Inc. - ADC Therapeutics Sarl - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Ajinomoto Pharmaceuticals Co., Ltd. - AlbireoPharma - Allozyne, Inc. - Almirall, S.A. - Amgen Inc. - Anacor Pharmaceuticals, Inc. - AnaptysBio, Inc. - Arena Pharmaceuticals, Inc. - Argos Therapeutics, Inc. - Arrien Pharmaceuticals, LLC - AstraZeneca Plc - Athenex, Inc. - Aurigene Discovery Technologies Limited - Avesthagen Limited - Avexxin AS - Basilea Pharmaceutica AG - BIOCAD - Biocon Limited - BioLingus AG - BioMAS Ltd. - Bionomics Limited - Bionovis SA - Boehringer Ingelheim GmbH - Brickell Biotech, Inc. - Bristol-Myers Squibb Company - Can-Fite BioPharma Ltd. - Celgene Corporation - Cellceutix Corporation For more information visit http://www.researchandmarkets.com/research/6tv9lw/psoriasis
AMGN: 150.65 (+1.03), BMY: 70.96 (+0.29), CANF: 2.67 (+0.05), ARGS: 5.71 (+0.10), AZN: 28.42 (+0.84), ANAC: 99.26 (+0.09), ARNA: 1.90 (+0.06), CELGZ: 1.45 (-0.02)
Colorectal Cancer Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/44bmjz/colorectal_cancer) has announced the addition of the "Colorectal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colorectal Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Colorectal CancerOverview - Therapeutics Development - Pipeline Products for Colorectal Cancer- Overview - Pipeline Products for Colorectal Cancer- Comparative Analysis - Colorectal Cancer- Therapeutics under Development by Companies - Colorectal Cancer- Therapeutics under Investigation by Universities/Institutes - Colorectal Cancer- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Colorectal Cancer- Products under Development by Companies - Colorectal Cancer- Products under Investigation by Universities/Institutes - Colorectal Cancer- Companies Involved in Therapeutics Development Companies Mentioned - Sample List of the 200 Companies Featured - 2cureX ApS - 3-V Biosciences, Inc. - 4SC AG - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Actinium Pharmaceuticals, Inc. - Adamed Sp. z o.o. - Advaxis, Inc. - Advenchen Laboratories, LLC - Alchemia Limited - Allinky Biopharma - Amgen Inc. - Antibe Therapeutics, Inc. - Apexigen, Inc. - Aphios Corporation - Aposense Ltd. - Arisaph Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Bavarian Nordic A/S - Baxalta Incorporated - Bayer AG - BeiGene(Beijing) Co.,Ltd - BioAtla, LLC - Biocon Limited - Bionomics Limited - Bionovis SA - Biotecnol, Inc. For more information visit http://www.researchandmarkets.com/research/44...tal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ADXS: 8.51 (+0.48), ARQL: 1.75 (-0.04), AMGN: 150.65 (+1.03), ATNM: 1.77 (-0.03), AZN: 28.42 (+0.84), AVEO: 1.01 (-0.01), ABBV: 60.11 (+0.10), BXLT: 46.02 (-0.18), ARRY: 3.28 (+0.03)
Inflammatory Bowel Disease Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/bgntqd/inflammatory) has announced the addition of the "Inflammatory Bowel Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Inflammatory Bowel Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Inflammatory Bowel Disease Overview - Therapeutics Development - Pipeline Products for Inflammatory Bowel Disease - Overview - Pipeline Products for Inflammatory Bowel Disease - Comparative Analysis - Inflammatory Bowel Disease - Therapeutics under Development by Companies - Inflammatory Bowel Disease - Therapeutics under Investigation by Universities/Institutes - Inflammatory Bowel Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Inflammatory Bowel Disease - Products under Development by Companies - Inflammatory Bowel Disease - Products under Investigation by Universities/Institutes - Inflammatory Bowel Disease - Companies Involved in Therapeutics Development Sample List of the 180 Companies - 4D Pharma Plc - 4SC AG - AB Science SA - AbbVie Inc. - Advinus Therapeutics Ltd. - Aerpio Therapeutics, Inc. - Ajinomoto Pharmaceuticals Co., Ltd. - Akari Therapeutics, Plc - Alba Therapeutics Corporation - AlbireoPharma - Alfa Wassermann S.p.A - Allozyne, Inc. - Altheus Therapeutics, Inc. - Alvine Pharmaceuticals, Inc. - Am-Pharma B.V. - Amakem NV - Amgen Inc. - Amorepacific Corporation - Ampio Pharmaceuticals, Inc. - Amyra Biotech AG - Apogee Biotechnology Corporation - Ardelyx, Inc. - Arena Pharmaceuticals, Inc. - Argos Therapeutics, Inc. - AskAt Inc. - Astellas Pharma Inc. - Atlantic Healthcare Plc - Avaxia Biologics, Inc. - Axxam SpA - Basilea Pharmaceutica AG - BioAtla, LLC - BIOCAD - BioLineRx, Ltd. - BioLingus AG - Bionovis SA - Biotec Pharmacon ASA - BioTherapeutics Inc. For more information visit http://www.researchandmarkets.com/research/bg...flammatory
ARGS: 5.71 (+0.10), AMGN: 150.65 (+1.03), AMPE: 3.22 (unch), ABBV: 60.11 (+0.10), AKTX: 14.61 (unch), ARNA: 1.90 (+0.06)
Basilea announces that European Commission approves isavuconazole (CRESEMBA(r)) as a treatment for invasive aspergillosis and mucormycosis in the European Union
GlobeNewswire - Fri Oct 16, 9:55AM CDT
-- Basilea's second anti-infective product approved in Europe, providing potential commercial synergy with Zevtera(R) (ceftobiprole)
Basilea signs exclusive distribution agreement for Zevtera(R) (ceftobiprole medocaril) in the Middle East and North Africa with Hikma Pharmaceuticals LLC
Thomson Reuters ONE - Thu Oct 15, 12:15AM CDT
Basilea Pharmaceutica AG / Basilea signs exclusive distribution agreement for Zevtera(R) (ceftobiprole medocaril) in the Middle East and North Africa with Hikma Pharmaceuticals LLC . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Basilea announces that Health Canada approved ZEVTERA(r) for the treatment of bacterial lung infections
GlobeNewswire - Mon Oct 12, 12:18AM CDT
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Health Canada has approved ZEVTERA (ceftobiprole medocaril) for the treatment of patients 18 years of age and older with hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP), and for the treatment of community-acquired pneumonia (CAP).
Gastric Cancer - Pipeline Review, H2 2015 Featuring Over 100 Companies
M2 - Mon Oct 05, 5:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lhb64g/gastric_cancer) has announced the addition of the "Gastric Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastric Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - 30 of the 100 Companies - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - AlphaVax, Inc. - Ambrx, Inc. - Amgen Inc. - Aslan Pharmaceuticals Pte. Ltd. - Astellas Pharma Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Azaya Therapeutics Incorporated - Basilea Pharmaceutica AG - Bayer AG - BioMarin Pharmaceutical Inc. - Biotecnol, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - cCAM Biotherapeutics Ltd. - Celgene Corporation - Celldex Therapeutics, Inc. - Cellectar Biosciences, Inc. - Celltrion, Inc. - Celon Pharma Sp. z o.o. - Cerulean Pharma, Inc. - Chipscreen Biosciences Ltd - Chugai Pharmaceutical Co., Ltd. - Curaxys, S.L. For more information visit http://www.researchandmarkets.com/research/lh...ric_cancer
CLRB: 3.54 (-0.10), ADXS: 8.51 (+0.48), BMRN: 84.06 (+0.20), CERU: 2.12 (+0.02), AMBX: (), CLDX: 4.41 (+0.14), AMGN: 150.65 (+1.03), BMY: 70.96 (+0.29), AZN: 28.42 (+0.84), AVEO: 1.01 (-0.01), ABBV: 60.11 (+0.10), CELGZ: 1.45 (-0.02)
Basilea announces development of inhaled dosage form of its Gram-negative antibiotic BAL30072 as part of European iABC program
GlobeNewswire - Mon Sep 07, 12:20AM CDT
-- Start of "inhaled Antibiotics in Bronchiectasis and Cystic fibrosis" (iABC) program to develop new antibiotic treatments for cystic fibrosis and bronchiectasis
Colorectal Cancer - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Colorectal Cancer
M2 - Fri Aug 14, 5:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dvsdxp/colorectal_cancer) has announced the addition of the "Colorectal Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colorectal Cancer and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - A review of the Colorectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Key Topics Covered: - Colorectal Cancer Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - 2cureX ApS - 3-V Biosciences, Inc. - 4SC AG - AB Science - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Adamed Sp. z o.o. - Advaxis, Inc. - Advenchen Laboratories, LLC - Aeterna Zentaris Inc. - Alchemia Limited - Allinky Biopharma - Amgen Inc. - Angiogene Pharmaceuticals Limited - Antibe Therapeutics, Inc. - Aphios Corporation - Arisaph Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Bavarian Nordic A/S - Bayer AG - Beta Cat Pharmaceuticals, LLC - Biocon Limited - Bionomics Limited - BioNovion B.V. - Biothera, Inc. - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company For more information visit http://www.researchandmarkets.com/research/dv...tal_cancer
ADXS: 8.51 (+0.48), ARQL: 1.75 (-0.04), AMGN: 150.65 (+1.03), BMY: 70.96 (+0.29), ATNM: 1.77 (-0.03), AZN: 28.42 (+0.84), AVEO: 1.01 (-0.01), ABBV: 60.11 (+0.10), ARRY: 3.28 (+0.03)
Basilea reports 2015 half-year results - Major milestones achieved for CRESEMBA(R) and Zevtera(R)
Thomson Reuters ONE - Fri Aug 14, 12:15AM CDT
Basilea Pharmaceutica AG / Basilea reports 2015 half-year results - Major milestones achieved for CRESEMBA(R) and Zevtera(R) . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of lung and skin infections
GlobeNewswire - Wed Aug 12, 12:20AM CDT
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) designated its investigational drug ceftobiprole as a Qualified Infectious Disease Product. The designation relates to the potential use of the drug in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Basilea reports topline results of isavuconazole phase 3 study in candidemia and other invasive Candida infections
Thomson Reuters ONE - Thu Jul 30, 12:15AM CDT
Basilea Pharmaceutica AG / Basilea reports topline results of isavuconazole phase 3 study in candidemia and other invasive Candida infections . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Basilea announces that CHMP recommends approval of isavuconazole (CRESEMBA(R)) as a treatment for invasive aspergillosis and mucormycosis in the European Union
Thomson Reuters ONE - Fri Jul 24, 6:46AM CDT
Basilea Pharmaceutica AG / Basilea announces that CHMP recommends approval of isavuconazole (CRESEMBA(R)) as a treatment for invasive aspergillosis and mucormycosis in the European Union . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
